APHA - Humana price target unchanged at Cantor despite Kindred deal; eyes on cannabis names as BofA resumes coverage; and more in today's analyst action

Cannabis stocks are in focus after Bank of America resumed coverage on several Canadian names in the sector including Canopy Growth, Tilray, and Cronos Group. But first on Cantor’s take on Humana - Kindred deal.Humana deal points to provider/payer convergence: CantorYesterday, after the market close, Humana (HUM) announced $8.1B worth of a transaction to acquire the remaining 60% interest in Kindred at Home.Weighing in on the development, Cantor Fitzgerald analyst Steven Halper calls the deal another example of provider/payer convergence.With Humana ruling out a material impact on 2021 earnings as a result, the analyst reiterates the overweight rating on the stock and the price target which at $450.00 implies only ~0.3% upside to the last close.According to the analyst, the company is likely to provide more details on the Kindred transaction on its Q1 2021 earnings call scheduled for today.Humana has added ~2.6% in the premarket after its revenue and earnings for Q1 2021 came ahead

For further details see:

Humana price target unchanged at Cantor despite Kindred deal; eyes on cannabis names as BofA resumes coverage; and more in today’s analyst action